Good Health is Your Greatest Wealth……Virgil
| The Food and Drug Administration is taking testimony this week as it weighs whether to approve the diet drug Qnexa, with a decision expected in mid-April. If the FDA decides to approve the appetite suppressant, it would be the first weight–loss drug to … See all stories on this topic » |
 Sarasota Herald-Tribune |
WASHINGTON (Reuters) – A Food and Drug Administration panel on Tuesday recommended GlaxoSmithKline Plc’s Votrient for treatment of advanced soft-tissue sarcoma, a relatively rare but aggressive form of cancer. The FDA advisory committee of outside experts voted 11-2 to find that the drug’s ability to improve short-term survival without worsening symptoms in patients who receive chemotherapy outweighed adverse risks and a lack of evidence that it can extend overall survival. (Reporting by David Morgan; Editing by Lisa Von Ahn)
WEDNESDAY, March 14 (HealthDay News) — The Israeli drug maker Teva Pharmaceuticals has gained the first U.S. approval to market generic Lexapro (escitalopram) to treat depression and general anxiety disorder, the U.S. Food and Drug Administration said Wednesday.
The Food and Drug Administration has received a complaint against a company that stored adult stem cells from Texas Governor Rick Perry for use in an experimental procedure to treat his back pain.
MONDAY, March 12 (HealthDay News) — A U.S. Food and Drug Administration advisory panel recommended on Monday that the makers of a new class of painkillers be given a second chance to develop the powerful drugs, despite concerns about joint failures.
WASHINGTON (Reuters) – U.S. drug regulators are asking experts for advice on whether companies should restart clinical trials for painkillers that help people with osteoarthritis and other conditions, but can destroy joints. The U.S. Food and Drug Administration said these drugs, from the class of anti-nerve growth factors, represent a potentially significant and novel strategy for the treatment of pain,” in a memo posted online on Thursday. …
LONDON (Reuters) – Regulators have rejected a move by AstraZeneca that could have delayed the entry of generic versions of its top-selling antipsychotic Seroquel onto the U.S. market later this month. Britain’s second biggest drugmaker said on Friday the Food and Drug Administration had denied its Citizen Petitions requesting the agency withhold finally approving any generic with labeling that did not have certain warning language required for its branded version. …
The US Food and Drug Administration is set to decide within weeks whether to okay the drug, billed as the first new weapon to combat obesity in more than a dozen years. The stakes are enormous. A diet pill that actually helps people lose weight without …
See all stories on this topic »
By David Fleshler, Sun Sentinel A Hollywood company's dietary supplements promised herbal solutions to problems of weight loss and male sexual performance. But the Food and Drug Administration says the supplement SlimXtreme contains a controversial …
See all stories on this topic »
WASHINGTON (Reuters) – A U.S. Food and Drug Administration chemist on Monday was sentenced to five years in federal prison after pleading guilty to insider trading by using confidential information about drug approvals. Cheng Yi Liang, 58, admitted buying and selling stock in more than two dozen companies with confidential FDA information to rack up just over $3.77 million in profits and avoid losses between July 2006 and March 2011. He pleaded guilty to two counts of securities fraud and making false statements. …
By Sam Baker The Food and Drug Administration next month is expected to say if it will approve Qnexa. A diet pill promising a ten percent weight loss could offer hope to a nation with an obesity rate near 35 percent. But Tammy Beaumont is concerned.
See all stories on this topic »
Last week, a US Food and Drug Administration advisory committee voted overwhelmingly to recommend approval of Qnexa. If officially approved later this spring, it will be the first new prescription weight–loss medication to appear on the market since …
See all stories on this topic »